Back to today’s briefing

Story perspectives

Jazz Pharmaceuticals to Acquire Chimerix for $935 Million

3/5/2025

25 6

Summary

Story summary

Jazz Pharmaceuticals is set to acquire Chimerix for around $935 million, offering $8.55 per share—a remarkable 72% premium. This all-cash deal focuses on securing dordaviprone, an experimental drug aimed at combating a rare brain tumor in children and young adults. The acquisition is anticipated to finalize in Q2 2025, pending regulatory approval.

1 of 1

Story summary

Jazz Pharmaceuticals is set to acquire Chimerix for around $935 million, offering $8.55 per share—a remarkable 72% premium. This all-cash deal focuses on securing dordaviprone, an experimental drug aimed at combating a rare brain tumor in children and young adults. The acquisition is anticipated to finalize in Q2 2025, pending regulatory approval.